Market Intelligence, Preclinical Progress, and High-Purity Reagents for Intracellular Trafficking, Oncology, and Retinal Degeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ARF4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ARF4 Recombinant / Mutant Protein (WT, Q71L, T31N) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ARF4 Products |
| Gene Delivery | ARF4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ARF4 Products |
| Benchmark Ab | Anti-ARF4 Recombinant Antibody High-specificity positive control for IP/Western and assay benchmarking. |
View ARF4 Products |
| Validator | ARF4 siRNA Set For knockdown verification and phenotypic screening. |
View ARF4 Products |
| Related Target A | ARF1 Closest paralog for subfamily selectivity and off-target counter-screening. |
View ARF1 Products |
| Related Target B | GBF1 Upstream GEF; co-targeting strategy for ARF4 pathway modulation. |
View GBF1 Products |
| Related Target C | RHO Essential cargo of ARF4-mediated vesicular transport in photoreceptors. |
View RHO Products |
| Related Target D | EGFR ARF4 mediates intracellular trafficking and downstream signaling of EGFR. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ARF Subfamily Isoform Selectivity (ARF1/ARF3/ARF5/ARF6 off-target) | Homolog Panel Proteins (ARF1/ARF4/ARF5/ARF6) strictly verified by Mass Spec; Sequence Verified with >95% purity. |
| GTP/GDP Conformational State Discrimination | Mutant Panel: Q71L (GTP-locked), T31N (GDP-locked); Theoretical MW confirmed; High batch-to-batch consistency. |
| Lack of Functional Controls | Full-length Lentivirus ORF + siRNA combo for rescue and knockdown validation; Clinical Benchmark Antibodies included for reliable baseline establishment. |
| False Positives / Assay Specificity | Sequence-verified siRNA included; Anti-ARF4 Ab validated by antigen pre-adsorption. |
Live ARF4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ARF4-targeted therapeutics is intensifying as researchers uncover its critical role in vesicular trafficking, tumor metastasis, and retinal ciliopathies. While traditional small GTPase targets have historically been challenging to drug due to high picomolar affinity for cellular GTP, the success of recent allosteric inhibitors is shifting focus toward targeting ARF4. As first-generation indirect approaches (e.g., GEF-targeting small molecules) advance through target validation, the next wave of R&D is targeting allosteric pocket discovery and targeted protein degradation (PROTACs) to overcome traditional occupancy-driven pharmacology limitations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / shRNA / RNAi / ASO | Academic & Biotech Discovery Programs; Gene Therapy Biotechs | Solid Tumors, Metastatic Disease, Retinal Degeneration | Knockdown Validation (Need high-specificity siRNA & Lentivirus rescue; Sequence Verified siRNA and stable cell lines) |
| Small Molecule (Indirect / GEF inhibitors / Allosteric) | Early-Stage Pharma Pipelines; Academic Consortia, Early Biotech | Oncology, Viral Infection, Glioblastoma, Breast Cancer | Selectivity Assay (Need ARF Isoform Mutant Panel vs. WT); Binding Assays (Need structural-grade high-purity recombinant proteins) |
| Biologics / Peptide PPI Disruptors | Emerging Biotech Ventures | Refractory Cancers | Conformational Binding Assay (Need GTP-locked / GDP-locked ARF4 mutants) |
| PROTAC / Degrader | Emerging Innovators | Refractory Solid Tumors | Ternary Complex Formation (Need purified mutant and WT ARF4 proteins) |
Key Mutation and Target Identity
- Key Mutation: dbSNP:rs11550597 (UniProt P18085 VAR_048317) – a documented variant in ARF4.
- Target Identity: ARF4 (UniProt P18085 primary entry) is the confirmed target, with no evidence of off-target misidentification.
Conclusion
ARF4 remains a high-value but challenging target in the preclinical space. TarMart's comprehensive reagent ecosystem—including mutant proteins, lentiviral ORFs, benchmark antibodies, and siRNA sets—directly addresses critical assay challenges such as isoform selectivity, conformational state discrimination, and functional validation. By integrating related targets like ARF1, GBF1, RHO, and EGFR, researchers can build robust pathway-level screening platforms to accelerate drug discovery.